Recently developed strategy for prevention of cancer relapse due to acquired radioresistance may be based on immunotherapies. One promising approach is based on genetically modified T cells expressing chimeric antigen receptors (CAR).
EXBIO the leading manufacturer of monoclonal antibodies and reagents for research and clinical applications with the focus on multi-color flow cytometry analysis of human cellular markers, is pleased to announce its acquisition of Apronex
EXBIO has recently developed two new products for multicolor flow-cytometric immunophenotyping of cells of the human immune system from peripheral blood to follow up kinetics of immune responses in relation to clinical and virological features of a COVID-19 patients.
Now, we bring you a presentation of patient’s data – comparision with percentage range acquired from normal healthy donors and time-course changes in subpopulations of B and T cells of hospitalized patients diagnosed with COVID-19.